These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 37251947)

  • 21. Real-world Therapeutic Outcomes of the Pembrolizumab Regimen as First-line Therapy for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: A Single-center Retrospective Cohort Study in Japan.
    Sano D; Tokuhisa M; Takahashi H; Hatano T; Nishimura G; Ichikawa Y; Oridate N
    Anticancer Res; 2022 Sep; 42(9):4477-4484. PubMed ID: 36039457
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Severe immune-related hepatitis and myocarditis caused by PD-1 inhibitors in the treatment of triple-negative breast cancer: a case report.
    Yang Y; Wu Q; Chen L; Qian K; Xu X
    Ann Transl Med; 2022 Apr; 10(7):424. PubMed ID: 35530956
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mycophenolate mofetil as a successful treatment of corticosteroid-resistant immune checkpoint inhibitor-induced hepatitis.
    Nakano K; Nishizawa M; Fukuda N; Urasaki T; Wang X; Mitani H; Takahashi S
    Oxf Med Case Reports; 2020 Apr; 2020(4):omaa027. PubMed ID: 32477577
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pembrolizumab-induced pancytopenia in a patient with squamous cell lung cancer.
    Ueki Y; Suzuki M; Horikawa Y; Watanabe H; Yamaguchi Y; Morita C; Tsukada A; Takumida H; Kusaba Y; Katsuno T; Tsujimoto Y; Sakamoto K; Hashimoto M; Terada J; Ishii S; Takasaki J; Naka G; Iikura M; Izumi S; Takeda Y; Hojo M; Sugiyama H
    Thorac Cancer; 2020 Sep; 11(9):2731-2735. PubMed ID: 32767641
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pembrolizumab-induced severe oral mucositis in a patient with squamous cell carcinoma of the lung: A case study.
    Yoon SY; Han JJ; Baek SK; Kim HJ; Maeng CH
    Lung Cancer; 2020 Sep; 147():21-25. PubMed ID: 32652370
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Case Report: Severe Immune-Related Cholestatic Hepatitis and Subsequent Pneumonia After Pembrolizumab Therapy in a Geriatic Patient With Metastic Gastric Cancer.
    Yang H; Zhou C; Yuan F; Guo L; Yang L; Shi Y; Zhang J
    Front Med (Lausanne); 2021; 8():719236. PubMed ID: 34712676
    [No Abstract]   [Full Text] [Related]  

  • 27. Relationship between Programmed Cell Death Protein Ligand 1 Expression and Immune-related Adverse Events in Non-small-cell Lung Cancer Patients Treated with Pembrolizumab.
    Sugisaka J; Toi Y; Taguri M; Kawashima Y; Aiba T; Kawana S; Saito R; Aso M; Tsurumi K; Suzuki K; Shimizu H; Ono H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y; Sugawara S
    JMA J; 2020 Jan; 3(1):58-66. PubMed ID: 33324776
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.
    Sun X; Roudi R; Dai T; Chen S; Fan B; Li H; Zhou Y; Zhou M; Zhu B; Yin C; Li B; Li X
    BMC Cancer; 2019 Jun; 19(1):558. PubMed ID: 31182061
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma in an Asian population.
    Chen WC; Chu PY; Lee YT; Lu WB; Liu CY; Chang PM; Yang MH
    Medicine (Baltimore); 2017 Dec; 96(52):e9519. PubMed ID: 29384959
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A case of panuveitis and retinal vasculitis associated with pembrolizumab therapy for metastatic lung cancer.
    Kim KW; Kusuhara S; Tachihara M; Mimura C; Matsumiya W; Nakamura M
    Am J Ophthalmol Case Rep; 2021 Jun; 22():101072. PubMed ID: 33796799
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Severe immune checkpoint inhibitor-associated gastritis: A case series and literature review.
    Sugiyama Y; Tanabe H; Matsuya T; Kobayashi Y; Murakami Y; Sasaki T; Kunogi T; Takahashi K; Ando K; Ueno N; Kashima S; Moriichi K; Tanino M; Mizukami Y; Fujiya M; Okumura T
    Endosc Int Open; 2022 Jul; 10(7):E982-E989. PubMed ID: 35845030
    [No Abstract]   [Full Text] [Related]  

  • 32. Neoadjuvant treatment of pembrolizumab plus platinum-doublet chemotherapy in stage IIIA squamous cell carcinoma of the lung: a case report.
    Zhang C; Jiang W; Li G; Li J; Kang Y; Yu X; Ma H; Feng Y
    Ann Palliat Med; 2021 Mar; 10(3):3510-3517. PubMed ID: 33849133
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pembrolizumab-induced myasthenia gravis-like disorder, ocular myositis, and hepatitis: a case report.
    Tian CY; Ou YH; Chang SL; Lin CM
    J Med Case Rep; 2021 Apr; 15(1):244. PubMed ID: 33926558
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
    Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
    Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of immune-related adverse events and anti-tumor efficacy following immune checkpoint inhibitor therapy in Japanese patients with various solid tumors.
    Yoshikawa Y; Imamura M; Yamauchi M; Hayes CN; Aikata H; Okamoto W; Miyata Y; Okada M; Hattori N; Sugiyama K; Yoshioka Y; Toratani S; Takechi M; Ichinohe T; Ueda T; Takeno S; Kobayashi T; Ohdan H; Teishima J; Hide M; Nagata Y; Kudo Y; Iida K; Chayama K
    BMC Cancer; 2022 Nov; 22(1):1232. PubMed ID: 36447159
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Unusual severe gastritis and gastric ulcers caused by pembrolizumab.
    Liu WT; Li YF; Hsieh TY
    J Postgrad Med; 2022; 68(1):38-40. PubMed ID: 34121670
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of Pembrolizumab in Recurrent/Metastatic Squamous Cell Head and Neck Carcinoma: A Multicenter Retrospective Study.
    Okada T; Fushimi C; Matsuki T; Tokashiki K; Takahashi H; Okamoto I; Sato H; Kondo T; Hanyu K; Kishida T; Ito T; Yamashita G; Masubuchi T; Tada Y; Miura K; Omura GO; Yamashita T; Oridate N; Tsukahara K
    Anticancer Res; 2023 Jun; 43(6):2717-2724. PubMed ID: 37247908
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mycophenolate mofetil for immune checkpoint inhibitor-related hepatotoxicity relapsing during dose reduction of corticosteroid: A report of two cases and literature review.
    Ueno M; Takabatake H; Hata A; Kayahara T; Morimoto Y; Notohara K; Mizuno M
    Cancer Rep (Hoboken); 2022 Sep; 5(9):e1624. PubMed ID: 35575047
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of Skin Rash Predicts Outcome of Anti-PD-1- and Anti-CTLA4-Based Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer or Squamous Cell Carcinoma of the Head and Neck: A Single-Center Analysis.
    Mayer K; Briese W; Blieninger J; Brossart P; Bisht S; Feldmann G
    Oncol Res Treat; 2021; 44(10):538-546. PubMed ID: 34515189
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.